» Authors » Alexandra Zahn

Alexandra Zahn

Explore the profile of Alexandra Zahn including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 680
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lindner K, Kussmann J, Fendrich V, Iwen K, Zahn A
Minerva Endocrinol (Torino) . 2023 Apr; 50(1):15-23. PMID: 37021921
Background: Predicting a multiple gland disease (MGD) in primary hyperparathyroidism (pHPT) remains challenging. This study aimed to evaluate predictive factors for MGD. Methods: A retrospective chart review was performed of...
2.
Iwen K, Kussmann J, Fendrich V, Lindner K, Zahn A
World J Surg . 2022 Jun; 46(9):2197-2205. PMID: 35705875
Background: Primary hyperparathyroidism (pHPT) is well treatable surgically. Sonography (US) and sestamibi scintigraphy (MIBI) are used routinely, but it is unclear how valuable they are in determining Parathyroid glands' different...
3.
Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra N, Cardoso L, et al.
Eur J Endocrinol . 2021 Dec; 186(2):R33-R63. PMID: 34863037
This European expert consensus statement provides recommendations for the diagnosis and management of primary hyperparathyroidism (PHPT), chronic hypoparathyroidism in adults (HypoPT), and parathyroid disorders in relation to pregnancy and lactation....
4.
Lenschow C, Schragle S, Kircher S, Lorenz K, Machens A, Dralle H, et al.
Ann Surg . 2020 Jul; 275(2):e479-e487. PMID: 32649472
Objective: In this retrospective cohort study, we describe the clinical presentation and workup of parathyroid carcinoma (PC) and determine its clinical prognostic parameters. Primary outcome was recurrence free survival. Summary...
5.
Steinebrunner N, Sandig C, Sommerer C, Hinz U, Giese T, Stremmel W, et al.
Ann Transplant . 2014 Jan; 19:32-40. PMID: 24457606
Background: Due to considerable pharmacokinetic (PK) variability, immunosuppression with calcineurin inhibitors (CNIs) remains challenging. The objective of this study was to assess a pharmacodynamic (PD) approach of monitoring nuclear factor...
6.
Zahn A, Mueller F, Hinz U, Schemmer P, Stremmel W, Ganten T
Ann Transplant . 2013 Oct; 18:525-32. PMID: 24088725
Background: Because the immunosuppressive regimen is a modifiable risk factor after orthotopic liver transplantation (OLT), physicians are nowadays aiming at an optimized and individualized strategy for each patient. The aim...
7.
Gauss A, Buchholz I, Zahn A, Schmitz G, Stremmel W, Fuellekrug J, et al.
Int J Med Sci . 2013 Aug; 10(10):1259-70. PMID: 23983584
Background And Aims: The etiopathogenesis of inflammatory bowel diseases (IBD) remains largely unexplained. Flotillins (flotillin-1 and flotillin-2) are ubiquitous proteins which have been linked to inflammation and regeneration. We hypothesized...
8.
Zahn A, Seubert L, Junger J, Schellberg D, Weiss K, Schemmer P, et al.
Ann Transplant . 2013 Jul; 18:327-35. PMID: 23817439
Background: Health-related quality of life (HRQOL) following orthotopic liver transplantation (OLT) has become increasingly important. Therefore, we aimed to identify factors affecting HRQOL after OLT. Material And Methods: This cross-sectional,...
9.
Braun A, Schonfeld U, Welsch T, Kadmon M, Funke B, Gotthardt D, et al.
Int J Colorectal Dis . 2011 Apr; 26(8):989-98. PMID: 21455745
Purpose: There is increasing evidence that a defect of the gastrointestinal mucosal barrier is important for the development of inflammatory bowel diseases (IBD). The hydrophobicity of the colonic mucosal surface...
10.
Zahn A, Schott N, Hinz U, Stremmel W, Schmidt J, Ganten T, et al.
Liver Transpl . 2011 Mar; 17(4):466-73. PMID: 21445930
Long-term calcineurin inhibitor (CNI) treatment can cause serious side effects in liver allograft recipients. An optimal risk-to-benefit ratio for CNI blood levels has not been established. Pharmacodynamic drug monitoring through...